愈肝颗粒治疗慢性乙型肝炎基本核心区启动子变异患者的疗效观察

Observation on Effect of Yugan Granule in Treating Patients of Chronic Hepatitis B with Basic Core Promoter Mutant Hepatitis B Virus

目的:观察中药制剂愈肝颗粒治疗慢性乙型肝炎（CHB）基本核心区启动子（BCP）变异患者的疗效。方法:用微孔板杂交法和酶联免疫吸附试验联合检测乙型肝炎病毒（HBV）BCP变异,变异阳性组（简称P组,46例）和变异阴性组（简称N组,69例）。所有患者均给予愈肝颗粒治疗,观察患者治疗前后临床表现及实验室有关指标。结果:治疗结束后,两组患者症状积分显著减低,血清ALT、TBiL水平明显下降。P组HBeAg阴转率（60％）显著高于N组（30％,P<0.05）,而HBV-DNA阴转两组比较差异无显著性,两组综合疗效相似。结论:愈肝颗粒能够显著改善CHB患者的症状,降低血清ALT和TBiL水平,同时具有抗HBV作用,且对于BCP变异株感染与野生株感染同等有效。

Objective: To observe the effect of Yugan Granule (YGG) in treating patients of chronic hepatitis B infected with basic core promoter (BCP) mutant HBV. Methods: BCP mutation was detected by microwell liquid hybridization combined with enzyme linked immunosorbent assay (ELISA) and 46 patients were confirmed to be the mutant positive (Group A), and 69 the mutant negative (Group B). All patients were treated by YGG and the clinical symptoms and laboratory parameters before and after treatment were observed. Results: The scores of symptoms and serum levels of alanine transaminase (ALT) and total bilirubin (TBil) were decreased markedly in both groups after treatment. The HBeAg negative conversion rate in Group A was 60 %, obviously higher than that in Group B(30%, P<0.05), while HBV-DNA negative conversion rate between the two groups had the insignificant difference. The overall efficacy was similar in the two groups. Conclusion: YGG could remarkably alleviate the symptoms, reduce serum levels of ALT and TBil, and showed the effect of anti- HBV with the same efficacy both to BCP mutant and wild strain HBV infected patients.